Intelligent Bio Solutions (NASDAQ:INBS – Get Rating) is one of 223 public companies in the "Surgical & medical instruments" industry, but how does it weigh in compared to its rivals? We will compare Intelligent Bio Solutions to similar businesses based on the strength of its valuation, profitability, analyst recommendations, institutional ownership, dividends, risk and earnings.
Risk & Volatility
Intelligent Bio Solutions has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Comparatively, Intelligent Bio Solutions' rivals have a beta of 1.37, indicating that their average share price is 37% more volatile than the S&P 500.
Get Intelligent Bio Solutions alerts:Profitability
This table compares Intelligent Bio Solutions and its rivals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Intelligent Bio Solutions | -1,078.91% | -106.09% | -62.08% |
| Intelligent Bio Solutions Competitors | -1,355.92% | -145.04% | -26.44% |
Insider and Institutional Ownership
2.3% of Intelligent Bio Solutions shares are owned by institutional investors. Comparatively, 45.3% of shares of all "Surgical & medical instruments" companies are owned by institutional investors. 1.9% of Intelligent Bio Solutions shares are owned by insiders. Comparatively, 15.0% of shares of all "Surgical & medical instruments" companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.Analyst Ratings
This is a summary of recent ratings and recommmendations for Intelligent Bio Solutions and its rivals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Intelligent Bio Solutions | 0 | 0 | 0 | 0 | N/A |
| Intelligent Bio Solutions Competitors | 900 | 3417 | 7595 | 172 | 2.58 |
As a group, "Surgical & medical instruments" companies have a potential upside of 23.20%. Given Intelligent Bio Solutions' rivals higher probable upside, analysts plainly believe Intelligent Bio Solutions has less favorable growth aspects than its rivals.
Earnings and Valuation
This table compares Intelligent Bio Solutions and its rivals top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Intelligent Bio Solutions | $440,000.00 | -$8.31 million | -2.12 |
| Intelligent Bio Solutions Competitors | $1.10 billion | $81.57 million | 10.59 |
Intelligent Bio Solutions' rivals have higher revenue and earnings than Intelligent Bio Solutions. Intelligent Bio Solutions is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Summary
Intelligent Bio Solutions rivals beat Intelligent Bio Solutions on 7 of the 10 factors compared.
Intelligent Bio Solutions Company Profile
(Get Rating)
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Receive News & Ratings for Intelligent Bio Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intelligent Bio Solutions and related companies with MarketBeat.com's FREE daily email newsletter.